Learn about Stop Loss industry claim trends, including the impact of gene and cell therapies, and how they are affecting claim costs for self-funded employers.
Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it's even more challenging to incorporate unbranded biologics and biosimilars into benefits plans.